Presidio Pharmaceuticals makes appointment
This article was originally published in Scrip
Executive Summary
Presidio Pharmaceuticals, a US speciality pharma company focused on the discovery, in-licensing, development and commercialisation of therapeutics for viral infections, including HIV-1 and hepatitis C, has named Tom Anderton vice-president of intellectual property and legal affairs. He previously served as associate general counsel at Monogram Biosciences. Before that, Mr Anderton was lead attorney, oncology, at Genencor.